Aethlon Medical Inc., a company specializing in medical therapeutics aimed at treating cancer and infectious diseases, has announced a public offering valued at $4.5 million. The offering includes 5,000,000 shares of common stock or pre-funded warrants, accompanied by warrants to purchase an equal number of shares. Each share or pre-funded warrant, along with the accompanying warrant, is priced at $0.90. The warrants are immediately exercisable and will expire five years from the date of issuance. Maxim Group LLC is serving as the exclusive placement agent for this offering. The proceeds are intended for general corporate purposes, including clinical trials, research and development, capital expenditures, and working capital.